LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC
P.A. Jänne(Dana-Farber Cancer Institute), D. Planchard(Université Paris-Saclay), K. Kobayashi(Saitama Medical University), J.C-H. Yang(National Taiwan University Hospital), Jiang Zhu(Jilin Province Tumor Hospital), Chee Khoon Lee(St George Hospital), Isamu Okamoto(Kyushu University), T.V. Tran(University Medical Center HCMC), S-W. Kim(Ulsan College), P-H. Feng(Taipei Medical University-Shuang Ho Hospital), Igor Andrašina(Národný Onkologický Ústav), J-M. Maurel(University of Cape Town), J.Y. Tan Chun Bing(Cebu Doctors' University), M. Pérol(Centre de Recherche en Cancérologie de Lyon), J.E. Cundom(Instituto de Diagnóstico e Investigaciones Metabólicas), Jacqulyne Robichaux(AstraZeneca (Brazil)), S. Paterson(AstraZeneca (Singapore)), Edgar Monterroso(AstraZeneca (Spain)), Muna Albayaty(AstraZeneca (Poland)), Niki Lama(Instituto Nacional de Enfermedades Neoplásicas)
Cited by 3Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis